Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Glycoprotein – e.g. – mucins – proteoglycans – etc.
Reexamination Certificate
2000-06-27
2003-06-24
Kunz, Gary (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Glycoprotein, e.g., mucins, proteoglycans, etc.
C530S350000, C514S002600, C514S008100, C424S194100, C424S195110
Reexamination Certificate
active
06583272
ABSTRACT:
BACKGROUND OF THE INVENTION
Erythropoiesis is the production of red blood cells, which occurs to offset cell destruction. Erythropoiesis is a controlled physiological mechanism that enables sufficient red blood cells to be available for proper tissue oxygenation. Naturally occurring human erythropoietin (hEPO) is produced in the kidney and is the humoral plasma factor which stimulates red blood cell production (Carnot, P and Deflandre, C (1906) C. R. Acad. Sci. 143: 432; Erslev, A J (1953 Blood 8: 349; Reissmann, K R (1950) Blood 5: 372; Jacobson, L O, Goldwasser, E, Freid, W and Plzak, L F (1957) Nature 179: 6331-4). Naturally occurring EPO stimulates the division and differentiation of committed erythroid progenitors in the bone marrow and exerts its biological activity by binding to receptors on erythroid precursors (Krantz, B S (1991) Blood 77: 419).
Erythropoietin has been manufactured biosynthetically using recombinant DNA technology (Egrie, J C, Strickland, T W, Lane, J et al. (1986) Immunobiol. 72: 213-224) and is the product of a cloned human EPO gene inserted into and expressed in the ovarian tissue cells of the chinese hamster (CHO cells). The primary structure of the predominant, fully processed form of hEPO is illustrated in SEQ ID NO:1. There are two disulfide bridges between Cys
7
-Cys
161
and Cys
29
-Cys
33
. The molecular weight of the polypeptide chain of EPO without the sugar moieties is 18,236 Da. In the intact EPO molecule, approximately 40% of the molecular weight are accounted for by the carbohydrate groups that glycosylate the protein at glycosylation sites on the protein (Sasaki, H, Bothner, B, Dell, A and Fukuda, M (1987) J. Biol. Chem. 262: 12059).
Because human erythropoietin is essential in red blood cell formation, the hormone is useful in the treatment of blood disorders characterized by low or defective red blood cell production. Clinically, EPO is used in the treatment of anemia in chronic renal failure patients (CRF) (Eschbach, J W, Egri, J C, Downing, M R et al. (1987) NEJM 316: 73-78; Eschbach, J W, Abdulhadi, M H, Browne, J K et al. (1989) Ann. Intern. Med. 111: 992; Egrie, J C, Eschbach, J W, McGuire, T, Adamson, J W (1988) Kidney Intl. 33: 262; Lim, V S, Degowin, R L, Zavala, D et al. (1989) Ann. Intern. Med. 110: 108-114) and in AIDS and cancer patients undergoing chemotherapy (Danna, R P, Rudnick, S A, Abels, R I In: M B, Garnick, ed. Erythropoietin in Clinical Applications—An International Perspective. New York, N.Y.: Marcel Dekker; 1990: p. 301-324). However, the bioavailability of commercially available protein therapeutics such as EPO is limited by their short plasma half-life and susceptibility to protease degradation. These shortcomings prevent them from attaining maximum clinical potency.
SUMMARY OF THE INVENTION
This invention provides an erythropoietin conjugate, said conjugate comprising an erythropoietin glycoprotein having at least one free amino group and having the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have sequence of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or a rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to “n” poly(ethylene glycol) groups of the formula —CO—(CH
2
)
x
—OCH
2
CH
2
)
m
—OR with the —CO (i.e. carbonyl) of each poly(ethylene glycol) group forming an amide bond with one of said amino groups; wherein R is lower alkyl; x is 2 or 3; m is from about 450 to about 900; n is from 1 to 3; and n and m are chosen so that the molecular weight of the conjugate minus the erythropoietin glycoprotein is from 20 kilodaltons to 100 kilodaltons. This invention further provides compositions containing conjugates described herein in which the percentage of conjugates in the composition in which n is 1 is at least ninety percent.
Compared to unmodified EPO (i.e., EPO without a PEG attached) and conventional PEG-EPO conjugates, the present conjugates have an increased circulating half-life and plasma residence time, decreased clearance, and increased clinical activity in vivo. The conjugates of this invention have the same uses as EPO. In particular, the conjugates of this invention are useful to treat patients by stimulating the division and differentiation of committed erythroid progenitors in the bone marrow in the same way EPO is used to treat patients.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4806524 (1989-02-01), Kawaguchi et al.
patent: 4902502 (1990-02-01), Nitecki et al.
patent: 4917888 (1990-04-01), Katre et al.
patent: 5641663 (1997-06-01), Garvin et al.
patent: 5672662 (1997-09-01), Harris et al.
patent: 5681811 (1997-10-01), Ekwuribe
patent: 6340742 (2002-01-01), Burg et al.
patent: 0154316 (1985-02-01), None
patent: 0605963 (1993-07-01), None
patent: 640619 (1995-03-01), None
patent: 668 353 (1995-08-01), None
patent: 0741187 (1996-11-01), None
patent: WO 95/05465 (1995-02-01), None
patent: WO 9911781 (1999-03-01), None
patent: WO 00 32772 (2000-06-01), None
patent: WO 01 02017 (2001-01-01), None
patent: WO 01 68141 (2001-09-01), None
patent: WO 01 76640 (2001-10-01), None
patent: WO 01 87329 (2001-11-01), None
Pascal Bailon and Wolfgang Berthold, Polyethylene glycol-conjugated pharmaceutical proteins (PSTT) vol. 1, No. 8, Nov. 1998, pp. 352-356.
DeBerry Regina M.
Hoffmann-La Roche Inc.
Johnston George W.
Kunz Gary
Rocha-Tramaloni Patricia S.
LandOfFree
Erythropoietin conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Erythropoietin conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Erythropoietin conjugates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3144917